Celldex Therapeutics (CLDX) Financials

$39.68

$0.31 (0.79%)

As on 04-Sep-2026 16:00EDT

Market cap

$3,116 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

4.3

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Operating Revenue	0.11	1.50	7.02	6.88	2.36	4.65
Cost of Revenue	63.79	--	163.55	118.01	82.26	53.31
Gross Profit	-63.67	1.50	-156.53	-111.13	-79.90	-48.66
Operating Expenses	262.19	288.90	38.55	43.41	35.33	22.58
Operating Profit (EBIT)	-325.86	-287.40	-195.08	-154.54	-115.23	-71.24
Other Income	--	--	--	--	--	0.51
Profit before Tax	-300.59	-258.80	-157.86	-141.43	-112.33	-70.74
Provision for Tax	--	--	-157.86	2.84	10.46	-0.23
Profit after Tax (Net Income)	-300.59	-258.80	-157.86	-141.43	-112.33	-70.51
Minority Interest	--	--	--	--	--	--
Consolidated Profit	--	--	--	--	-112.33	-70.51

Liabilities ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Shareholder's Funds	714.56	527.17	747.01	429.17	326.20	419.48
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	6.46	4.83	5.83	5.33	7.92	8.65
Current Liabilities	61.33	50.99	39.50	31.13	18.61	16.53
Total Liabilities	843.67	582.98	792.34	465.63	352.74	444.65

Assets ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Non-Current Assets	57.42	48.32	45.18	33.93	35.04	33.82
Current Assets	724.93	534.66	747.16	431.69	317.69	410.84
Total Assets	843.67	582.98	792.34	465.63	352.74	444.65
Total Debt*	4.90	2.34	3.81	2.54	4.03	3.04
Net Current Assets	663.61	483.67	707.66	400.57	299.08	394.31

Cashflow ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Cash From Operating Activities	--	-210.95	-157.78	-107.29	-103.73	-60.91
Cash Flow from Investing Activities	--	209.07	-290.13	-105.78	89.94	-216.16
Cash from Financing Activities	--	2.39	441.45	218.46	4.08	272.37
Net Cash Inflow / Outflow	--	--	--	--	--	-4.69

Financials Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Adjusted EPS ($)	-4.36	-3.89	-2.38	-2.72	-2.38	-1.51
Cash EPS ($)	-4.35	-3.84	-2.33	-2.66	-2.32	-1.44
Adjusted Book Value ($)	9.10	7.93	11.26	8.25	6.92	8.98
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	-3.17	-2.38	-2.06	-2.20	-1.30
Free Cash Flow per Share ($)	--	-3.21	-2.41	-2.10	-2.24	-1.33

Profitability Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
ROCE (%)	--	-40.43	-26.70	-37.12	-29.84	-22.20
ROE (%)	-48.42	-40.62	-26.84	-37.45	-30.13	-22.43
ROA (%)	-38.32	-37.63	-25.10	-34.56	-28.17	-20.72
EBIT Margin (%)	-268,385.71	-17,253.33	-2,248.76	-2,063.66	-4,543.74	-1,486.73
Net Margin (%)	-268,385.71	-17,253.33	-2,248.76	-2,054.76	-4,765.59	-1,367.55
Cash Profit Margin (%)	-0.08	--	--	--	--	--

Growth Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Revenue Growth (%)	-98.07	-0.79	0.02	1.92	-0.49	-0.37
EBIT Growth (%)	-50.59	-63.94	-11.14	-32.63	-54.88	-39.49
Net Profit Growth (%)	-50.59	-63.94	-11.62	-25.91	-59.30	-17.95
EPS Growth (%)	-44.92	-0.64	0.12	-0.14	-0.58	0.00
Book Value Growth (%)	-7.01	--	--	--	--	--

Valuation Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Price / Earnings	--	-6.98	-10.62	-14.59	-18.70	-25.59
Price / Book Value	4.32	3.43	2.24	4.81	6.44	4.30
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	-17.34	-5.05	-6.18	-11.83	-17.27	-21.17
Close Price ($)	37.21	27.16	25.27	39.66	44.57	38.64
High Price ($)	39.16	30.50	53.18	48.40	46.04	57.20
Low Price ($)	19.72	14.40	22.93	22.11	19.85	15.37
Market Cap ($ Cr)	3,116.05	--	--	--	--	--

Solvency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debt to Equity	--	0.00	0.01	0.01	0.01	0.01
Short term debt to equity ratio	0.00	0.00	0.00	0.00	0.00	0.00
Current Ratio	11.82	10.49	18.91	13.87	17.07	24.86
Quick Ratio	11.82	--	--	13.87	17.09	24.87
Interest Coverage	--	--	--	--	-36.82	-617.39

Operating Efficiency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debtors to sales (%)	205.36	134.33	9.97	65.79	14.72	3.70
Asset Turnover	0.00	0.00	0.01	0.02	0.01	0.01
Receivable days	--	330.55	136.01	129.35	40.21	77.51
Inventory Days	--	--	0.00	-0.54	-1.15	-6.76
Payable days	--	--	7.55	10.58	10.14	7.80
Cash Conversion Cycle	--	--	128.46	118.23	28.92	62.95

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.